[丹参盐酸川芎嗪鼻腔热敏原位凝胶的制备及鼻腔粘膜通透性表征研究]。

中药材 Pub Date : 2016-07-01

Wang-qing Hao, Yu Lin, Xu Yuan, Qian Gao

{"title":"[丹参盐酸川芎嗪鼻腔热敏原位凝胶的制备及鼻腔粘膜通透性表征研究]。","authors":"Wang-qing Hao, Yu Lin, Xu Yuan, Qian Gao","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: To prepare the salviae miltiorrhiza and ligustrazine hydrochloride nasal thermosensitive in situ gel and to study the characterization of its nasal mucosal permeability.Methods: With gelling temperature as the dependent variable, the contents of poloxamer 407( P407), poloxamer 188( P188) and PEG-6000 as independent variables. The best prescription was optimized by central composite design-response surface methodology. The release in vitro and the skin permeation ability were evaluated in Franz diffusion cell.Results: The optimal formulation composed with the dosage of P407,P188 and PEG-6000 were 18%,7% and 1%,respectively. The cumulative release in vitro was over 70% after 12 h, and the release curve conformed to the first-order kinetic equation. The cumulative permeation of salviae miltiorrhiza and ligustrazine hydrochloride in the gel were 2 649. 77 μg / cm2 and 119. 72 μg / cm2 after 12h.Conclusion: The central composite design-response surface methodolog was stable and feasible for preparation of nasal thermosensitive in situ gel of salviae miltiorrhiza and ligustrazine hydrochloride, the drug-loaded gel has sustained release effect.","PeriodicalId":15312,"journal":{"name":"中药材","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Preparation of Salviae Miltiorrhiza and Ligustrazine Hydrochloride Nasal Thermosensitive in Situ Gel and Study on Characterization of Its Nasal Mucosal Permeability].\",\"authors\":\"Wang-qing Hao, Yu Lin, Xu Yuan, Qian Gao\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To prepare the salviae miltiorrhiza and ligustrazine hydrochloride nasal thermosensitive in situ gel and to study the characterization of its nasal mucosal permeability.Methods: With gelling temperature as the dependent variable, the contents of poloxamer 407( P407), poloxamer 188( P188) and PEG-6000 as independent variables. The best prescription was optimized by central composite design-response surface methodology. The release in vitro and the skin permeation ability were evaluated in Franz diffusion cell.Results: The optimal formulation composed with the dosage of P407,P188 and PEG-6000 were 18%,7% and 1%,respectively. The cumulative release in vitro was over 70% after 12 h, and the release curve conformed to the first-order kinetic equation. The cumulative permeation of salviae miltiorrhiza and ligustrazine hydrochloride in the gel were 2 649. 77 μg / cm2 and 119. 72 μg / cm2 after 12h.Conclusion: The central composite design-response surface methodolog was stable and feasible for preparation of nasal thermosensitive in situ gel of salviae miltiorrhiza and ligustrazine hydrochloride, the drug-loaded gel has sustained release effect.\",\"PeriodicalId\":15312,\"journal\":{\"name\":\"中药材\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中药材\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中药材","FirstCategoryId":"3","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

目的:制备丹参盐酸川芎嗪鼻腔热敏原位凝胶，并对其鼻腔粘膜通透性进行表征。方法:以胶凝温度为因变量，以波洛沙姆407(P407)、波洛沙姆188(P188)、PEG-6000含量为自变量。采用中心设计-响应面法优选出最佳处方。在Franz扩散池中测定其体外释放度和透皮能力。结果:以P407、P188、PEG-6000的用量分别为18%、7%、1%组成的最佳处方。12 h体外累积释放量大于70%，释放曲线符合一级动力学方程。丹参与盐酸川芎嗪在凝胶中的累积渗透率为2 649。77 μg / cm2和119 μg / cm2。12h后72 μg / cm2。结论:采用中心设计-反应面法制备丹参盐酸川芎嗪鼻腔热敏原位凝胶稳定可行，该凝胶具有缓释效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

[Preparation of Salviae Miltiorrhiza and Ligustrazine Hydrochloride Nasal Thermosensitive in Situ Gel and Study on Characterization of Its Nasal Mucosal Permeability].

Objective: To prepare the salviae miltiorrhiza and ligustrazine hydrochloride nasal thermosensitive in situ gel and to study the characterization of its nasal mucosal permeability.

Methods: With gelling temperature as the dependent variable, the contents of poloxamer 407( P407), poloxamer 188( P188) and PEG-6000 as independent variables. The best prescription was optimized by central composite design-response surface methodology. The release in vitro and the skin permeation ability were evaluated in Franz diffusion cell.

Results: The optimal formulation composed with the dosage of P407,P188 and PEG-6000 were 18%,7% and 1%,respectively. The cumulative release in vitro was over 70% after 12 h, and the release curve conformed to the first-order kinetic equation. The cumulative permeation of salviae miltiorrhiza and ligustrazine hydrochloride in the gel were 2 649. 77 μg / cm2 and 119. 72 μg / cm2 after 12h.

Conclusion: The central composite design-response surface methodolog was stable and feasible for preparation of nasal thermosensitive in situ gel of salviae miltiorrhiza and ligustrazine hydrochloride, the drug-loaded gel has sustained release effect.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中药材

自引率

0.00%

发文量

11364

期刊介绍： "Chinese Materia Medica" magazine was founded in 1978. It is a national-level academic journal of Chinese medicine science and technology approved by the State Science and Technology Commission and the Press and Publication Administration for public distribution at home and abroad. It is sponsored by the Chinese Materia Medica Information Center of the State Food and Drug Administration and is publicly distributed at home and abroad. It mainly reports on new technologies, new methods and new achievements in the production, scientific research and business management of Chinese medicine, and serves to promote the production and scientific and technological development of Chinese medicine, improve the output and quality of Chinese medicine, improve business management, and prosper the Chinese medicine industry.